Alector AL002 INVOKE-2 Phase II Alzheimer’s trial misses goal
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD).
UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a string of investigational meds missing the mark in the indication. | Alector’s Abbvie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study,
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Jeffrey Hung has given his Sell rating due to a combination of factors, primarily driven by the unfavorable ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...
Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, ...
M.D., Chief Financial Officer of Alector. “We anticipate transformational data from both the AL002 INVOKE-2 Phase 2 trial and the latozinemab INFRONT-3 pivotal Phase 3 trial within our runway.
In October 2024, Alector published a manuscript titled“Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease” in Alzheimer's Research ...
H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...
This funding boosts its financial flexibility, allowing Alector to advance its pipeline, including the AL002 INVOKE-2 Phase 2 and latozinemab INFRONT-3 Phase 3 trials, and its innovative blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback